← back to search

Charlie Hatton

Dana-Farber Cancer Institute · US
Area of research
Molecular Biology · Hematology
Research interest
Research interests include Protein Degradation and Inhibitors, Acute Myeloid Leukemia Research, Histone Deacetylase Inhibitors Research, and Multiple Myeloma Research and Treatments.
h-index
28
citations
15,497
works
220
NIH funding
primary concept
Biology
email

Recent publications

KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in <i>NUP98</i> -Rearranged Acute Myeloid Leukemia
Cancer Discovery 2025cited by 10position: middledoi
Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer
Cell Reports Medicine 2025cited by 8position: middledoi
p300/CBP is an essential driver of pathogenic enhancer activity and gene expression in Ewing sarcoma
EMBO Reports 2025cited by 7position: middledoi
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of <i>KMT2A</i>-r and <i>NPM1c</i> AML
Blood 2023cited by 26position: middledoi
Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia
Cancer Discovery 2022cited by 121position: middledoi
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia
Nature Cancer 2022cited by 56position: middledoi
The menin-MLL1 interaction is a molecular dependency in <i>NUP98</i>-rearranged AML
Blood 2021cited by 137position: middledoi
Therapeutic targeting of preleukemia cells in a mouse model of <i>NPM1</i> mutant acute myeloid leukemia
Science 2020cited by 266position: middledoi
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Nature 2018cited by 111position: middledoi
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Nature 2012cited by 8,455position: middledoi
Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway
PLoS Genetics 2012cited by 634position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Scott A. Armstrong · Harvard University7 papers (2020–2025)Yanhe Wen · Dana-Farber Cancer Institute5 papers (2021–2025)Florian Perner · Universitätsmedizin Greifswald4 papers (2021–2023)Gerard M. McGeehan · Eloxx Pharmaceuticals (United States)4 papers (2020–2023)Jill A. Henrich · Dana-Farber Cancer Institute3 papers (2021–2023)Yana Pikman · Harvard University3 papers (2021–2023)Eric Wong · St Joseph's Health Care3 papers (2020–2022) · 3 papers (2022–2025)Hannah J. Uckelmann · Goethe University Frankfurt3 papers (2020–2022)Wallace Bourgeois · New York University3 papers (2022–2025)Jevon Cutler · Johns Hopkins Medicine2 papers (2022–2023)Brandon J. Aubrey · Harvard University2 papers (2022–2023)Radosław P. Nowak · University of Bonn2 papers (2022–2023)Eric S. Fischer · Harvard University2 papers (2022–2023)Katherine A. Donovan · Harvard University2 papers (2022–2023)Kimberly Stegmaier · Harvard University2 papers (2022–2025)Elena Haarer · University of Connecticut2 papers (2022–2025) · 2 papers (2023–2025)Meaghan Boileau · McGill University Health Centre2 papers (2023–2025) · 1 papers (2025–2025)